Rifaximin for Maintenance Therapy in Pouchitis
Author Information
Author(s): Shen Bo, Remzi Feza H, Lopez A Rocio, Queener Elaine
Primary Institution: The Cleveland Clinic
Hypothesis
Can rifaximin effectively maintain remission in patients with antibiotic-dependent pouchitis?
Conclusion
Rifaximin appears to be an effective maintenance therapy for patients with antibiotic-dependent pouchitis.
Supporting Evidence
- 65% of patients maintained remission at 3 months.
- Only one patient reported an adverse event.
- The median maintenance dose was 200 mg/day.
Takeaway
This study shows that a medicine called rifaximin can help people with a certain type of bowel problem stay better for a long time.
Methodology
Patients received rifaximin after a 2-week course of antibiotics and were followed for up to 24 months to assess remission.
Potential Biases
Potential bias due to the open-label design and lack of randomization.
Limitations
The study had an open-label design, lacked standardized dosing, and had incomplete endoscopy data for some patients.
Participant Demographics
Adult patients with antibiotic-dependent pouchitis, median age around 46 years.
Statistical Information
P-Value
p<0.0005
Statistical Significance
p<0.0005
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website